AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23974276 — intervention group
Group type: COMPARATOR
Intervention: MS+TDS- group
Number of subjects: 80
Study 21679040 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% mepivacaine with 1:100,000 norepinephrine
Number of subjects: 36
Study 21679040 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 36
Study 19365786 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin treatment for 3 months
Number of subjects: 144
Study 19365786 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 144
Study 16877720 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel, carboplatin, and etoposide (4 courses at 3-week intervals)
Number of subjects: 78
Study 16877720 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (weekly for 24 weeks after initial treatment for those with objective response or stable disease)
Number of subjects: 78
Study 16877720 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 78
Study 16877720 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxicity
Number of subjects: 78
Study 15526723 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis (group S)
Number of subjects: 102
Study 15526723 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic shock (group SS)
Number of subjects: 102
Study 15526723 — intervention group
Group type: COMPARATOR
Intervention: Control (group C)
Number of subjects: 102
Study 15526723 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis and septic shock (groups S and SS)
Number of subjects: 102
Study 11424516 — intervention group
Group type: COMPARATOR
Intervention: YGD capsules (three capsules before each main meal for 10 days)
Number of subjects: 44
Study 11424516 — intervention group
Group type: COMPARATOR
Intervention: YGD capsules (three capsules before each main meal for 45 days)
Number of subjects: 44
Study 11424516 — intervention group
Group type: EXPERIMENTAL
Intervention: YGD capsules (active treatment for 12 months)
Number of subjects: 44
Study 11424516 — intervention group
Group type: COMPARATOR
Intervention: YGD capsules
Number of subjects: 44
Study 10354964 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS melatonin (1 x 110 micrograms)
Number of subjects: 12
Study 10354964 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS melatonin (4 x 110 micrograms)
Number of subjects: 12
Study 10354964 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS melatonin
Number of subjects: 12
Study 7712308 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA (450 mg/day) for 6 months
Number of subjects: 101
Study 7712308 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 101
Study 2676224 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial cisplatin infusion
Number of subjects: 0
Study 2676224 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cisplatin infusion
Number of subjects: 0
Study 2676224 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial and intravenous cisplatin infusions
Number of subjects: 0
Study 28870 — intervention group
Group type: EXPERIMENTAL
Intervention: Clorazepate dipotassium (CZP) with 60 ml of water
Number of subjects: 10
Study 28870 — intervention group
Group type: COMPARATOR
Intervention: Clorazepate dipotassium (CZP) with 60 ml of magnesium aluminum hydroxide (Maalox)
Number of subjects: 10
Study 31706144 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg daily
Number of subjects: 5522
Study 31706144 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 5522
Study 27120190 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrally placed resorbable screw and sheath (BioIntrafix)
Number of subjects: 90
Study 27120190 — intervention group
Group type: COMPARATOR
Intervention: Eccentrically placed resorbable interference screw (BioRCI) and two non‐resorbable staples
Number of subjects: 90
Study 27120190 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study 27120190 — intervention group
Group type: EXPERIMENTAL
Intervention: Screw/sheath fixation
Number of subjects: 90
Study 26305064 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine (single oral dose)
Number of subjects: 18
Study 26305064 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single dose)
Number of subjects: 18
Study 26305064 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine (1-month treatment)
Number of subjects: 18
Study 23136857 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive emotional state
Number of subjects: 0
Study 23136857 — intervention group
Group type: COMPARATOR
Intervention: Negative emotional state
Number of subjects: 0
Study 23136857 — intervention group
Group type: COMPARATOR
Intervention: Neutral affective state
Number of subjects: 0
Study 23136857 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific affective states
Number of subjects: 0
Study 21508208 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDAS (Mediterranean Diet Adherence Screener)
Number of subjects: 7146
Study 21508208 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDAS
Number of subjects: 7146
Study 21508208 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher PREDIMED score
Number of subjects: 7146
Study 21508208 — intervention group
Group type: EXPERIMENTAL
Intervention: PREDIMED score
Number of subjects: 7146
Study 19706137 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell saving autotransfusion (Group A)
Number of subjects: 50
Study 19706137 — intervention group
Group type: COMPARATOR
Intervention: No cell saving autotransfusion (Group B)
Number of subjects: 50
Study 16690717 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal-only breathing (mouth taped)
Number of subjects: 8
Study 16690717 — intervention group
Group type: COMPARATOR
Intervention: Oral-only breathing (nose clip)
Number of subjects: 8
Study 15296690 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based personalized letter
Number of subjects: 0
Study 15296690 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored call delivered by community health care workers
Number of subjects: 0
Study 15296690 — intervention group
Group type: COMPARATOR
Intervention: Tailored letter
Number of subjects: 0
Study 15296690 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 11401930 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization of endothelial progenitor cells (EPCs) in patients with acute myocardial infarction
Number of subjects: 16
Study 11401930 — intervention group
Group type: COMPARATOR
Intervention: Control subjects with no evidence of cardiac ischemia
Number of subjects: 16
Study 11401930 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with acute myocardial infarction
Number of subjects: 16
Study 9368242 — intervention group
Group type: EXPERIMENTAL
Intervention: Fever duration <1 day
Number of subjects: 6680
Study 9368242 — intervention group
Group type: EXPERIMENTAL
Intervention: Fever duration <2 days
Number of subjects: 6680
Study 9368242 — intervention group
Group type: EXPERIMENTAL
Intervention: Fever duration 1-2 days
Number of subjects: 6680
Study 9459317 — intervention group
Group type: EXPERIMENTAL
Intervention: Third generation oral contraceptives (OCs)
Number of subjects: 201
Study 9459317 — intervention group
Group type: EXPERIMENTAL
Intervention: Other oral contraceptives (OCs)
Number of subjects: 201
Study 9459317 — intervention group
Group type: COMPARATOR
Intervention: Control group (no OCs)
Number of subjects: 201
Study 2694767 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance antipsychotic medication
Number of subjects: 49
Study 2694767 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 49
Study 2694767 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 49
Study 798592 — intervention group
Group type: EXPERIMENTAL
Intervention: Asa foetida (0.1% alcoholic dilution)
Number of subjects: 0
Study 798592 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Asa foetida and Nux vomica (0.01% alcoholic dilution)
Number of subjects: 0
Study 798592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31601389 — intervention group
Group type: EXPERIMENTAL
Intervention: CK‐MB elevation (≥5 × ULN)
Number of subjects: 13452
Study 31601389 — intervention group
Group type: EXPERIMENTAL
Intervention: cTn elevation (≥35 × ULN)
Number of subjects: 13452
Study 31601389 — intervention group
Group type: EXPERIMENTAL
Intervention: CK‐MB and cTn elevation
Number of subjects: 13452
Study 31601389 — intervention group
Group type: EXPERIMENTAL
Intervention: CK‐MB ratio (≥10) post‐procedure
Number of subjects: 13452
Study 31601389 — intervention group
Group type: EXPERIMENTAL
Intervention: cTn elevation
Number of subjects: 13452
Study 28760751 — intervention group
Group type: EXPERIMENTAL
Intervention: Multitarget therapy (tacrolimus, 2‐3mg/d; mycophenolate mofetil, 0.50‐0.75 g/d; prednisone, 10mg/d)
Number of subjects: 206
Study 28760751 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (2 mg/kg per day) plus prednisone (10 mg/d)
Number of subjects: 206
Study 28760751 — intervention group
Group type: EXPERIMENTAL
Intervention: Multitarget therapy
Number of subjects: 206
Study 28760751 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 206
Study 24560740 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programme for nurses regarding health care during disasters
Number of subjects: 207
Study 23760302 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP with interventional tumor removal (ITR)
Number of subjects: 52
Study 23760302 — intervention group
Group type: COMPARATOR
Intervention: PVP alone
Number of subjects: 52
Study 20409520 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemihepatic vascular inflow occlusion
Number of subjects: 180
Study 20409520 — intervention group
Group type: EXPERIMENTAL
Intervention: Main portal vein inflow occlusion
Number of subjects: 180
Study 20409520 — intervention group
Group type: EXPERIMENTAL
Intervention: Pringle maneuver
Number of subjects: 180
Study 18999981 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 40
Study 18999981 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 40
Study 17009303 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaf product
Number of subjects: 74
Study 17009303 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantegral design
Number of subjects: 74
Study 17009303 — intervention group
Group type: EXPERIMENTAL
Intervention: Small pad design
Number of subjects: 74
Study 17009303 — intervention group
Group type: COMPARATOR
Intervention: Pouch designs
Number of subjects: 74
Study 17009303 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaf designs
Number of subjects: 74
Study 14716385 — intervention group
Group type: EXPERIMENTAL
Intervention: Information campaign led by the Norwegian Cancer Society since 1995
Number of subjects: 1000
Study 11402254 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (HFD-CHO)
Number of subjects: 5
Study 11402254 — intervention group
Group type: COMPARATOR
Intervention: Habitual diet (CTL)
Number of subjects: 5
Study 9424001 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg p.o.
Number of subjects: 23
Study 9424001 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 30 mg p.o.
Number of subjects: 23
Study 9424001 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 60 mg p.o. (after dose increase)
Number of subjects: 23
Study 8306001 — intervention group
Group type: EXPERIMENTAL
Intervention: Peribulbar block (PB)
Number of subjects: 122
Study 8306001 — intervention group
Group type: COMPARATOR
Intervention: Retrobulbar block (RB)
Number of subjects: 122
Study 3743627 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble aspirin (1.2 g)
Number of subjects: 90
Study 3743627 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin tablets (1.2 g)
Number of subjects: 90
Study 3743627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 3743627 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble aspirin
Number of subjects: 90
Study 3743627 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin tablets
Number of subjects: 90
Study 31287198 — intervention group
Group type: EXPERIMENTAL
Intervention: Magee scores
Number of subjects: 0
Study 31287198 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (Oncotype DX)
Number of subjects: 0
Study 29500541 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.10% OCT rinse
Number of subjects: 90
Study 29500541 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% OCT rinse
Number of subjects: 90
Study 29500541 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.20% OCT rinse
Number of subjects: 90
Study 29500541 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 90
Study 26967681 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine 200 mg
Number of subjects: 10
Study 26967681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 24751658 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training group (TG)
Number of subjects: 76
Study 24751658 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 76
Study 22138847 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing and direct periodontal intrapocket application of 15% metronidazole‐based gel in two sites (>5 mm in depth)
Number of subjects: 16
Study 22138847 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (active control)
Number of subjects: 16
Study 21090335 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (Sishencong, Baihui, Shenting, etc.), once daily for 2 months.
Number of subjects: 300
Study 21090335 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20 mg/d), administered orally for 2 months.
Number of subjects: 300
Study 18681336 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention bonus program (intervention group)
Number of subjects: 70429
Study 18681336 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70429
Study 16178494 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin/β-lactam combination
Number of subjects: 8
Study 12914864 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise echocardiography (EE)
Number of subjects: 164
Study 12914864 — intervention group
Group type: COMPARATOR
Intervention: Baseline echocardiography and ECG treadmill exercise testing
Number of subjects: 164
Study 10577438 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin treatment (100 mg to 1000 mg daily)
Number of subjects: 52
Study 10577438 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin treatment
Number of subjects: 52
Study 10577438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 8696422 — intervention group
Group type: EXPERIMENTAL
Intervention: High-MCT diet (HMCT)
Number of subjects: 6
Study 8696422 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-MCT diet (MMCT)
Number of subjects: 6
Study 8696422 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-MCT diet (LMCT)
Number of subjects: 6
Study 1752603 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-hMG combination cycle
Number of subjects: 0
Study 1752603 — intervention group
Group type: COMPARATOR
Intervention: hMG cycle
Number of subjects: 0
Study 1752603 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-hMG cycle
Number of subjects: 0
Study 7040192 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestogen only (Lynestrenol 0.5 mg)
Number of subjects: 23
Study 7040192 — intervention group
Group type: COMPARATOR
Intervention: Combined oral contraceptive (ethinyl estradiol 50 micrograms + lynestrenol 2.5 micrograms)
Number of subjects: 23
Study 31858136 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter treatment duration (5-9 days)
Number of subjects: 408
Study 31858136 — intervention group
Group type: COMPARATOR
Intervention: Longer treatment duration (10-15 days)
Number of subjects: 408
Study 30967869 — intervention group
Group type: EXPERIMENTAL
Intervention: MBL2 rs1800450- AA genotype
Number of subjects: 1007
Study 30967869 — intervention group
Group type: EXPERIMENTAL
Intervention: High clinical risk score (≥1%) combined with MBL2 rs1800450-AA
Number of subjects: 1007
Study 30967869 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (carrying rs1800450-AA)
Number of subjects: 1007
Study 30967869 — intervention group
Group type: EXPERIMENTAL
Intervention: IgAN patients (carrying rs1800450-AA)
Number of subjects: 1007
Study 30261877 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Screening and Treatment (ISTp)
Number of subjects: 227
Study 30261877 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Preventive Treatment (IPTp)
Number of subjects: 227
Study 30261877 — intervention group
Group type: COMPARATOR
Intervention: Single Screen and Treat (SSTp)
Number of subjects: 227
Study 27381286 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose reduction regimen of etanercept (50 mg/week for 4 weeks followed by 25 mg/week for 8 weeks)
Number of subjects: 43
Study 27381286 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose of etanercept (50 mg/week for 12 weeks)
Number of subjects: 43
Study 25443043 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional development (five days) and group-based consultation (14 sessions) for early childhood teachers
Number of subjects: 100
Study 25443043 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (no intervention)
Number of subjects: 100
Study 23201982 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic nose analysis of stool samples before and four weeks after radiotherapy
Number of subjects: 23
Study 23201982 — intervention group
Group type: EXPERIMENTAL
Intervention: FAIMS analysis of stool samples before and four weeks after radiotherapy
Number of subjects: 23
Study 23201982 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment stool samples analysis
Number of subjects: 23
Study 18249383 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Therapy (HT)
Number of subjects: 120
Study 18249383 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 120
Study 18249383 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 120
Study 17577027 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate every-3-months depot (LAD-3M)
Number of subjects: 599
Study 17577027 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (CMF)
Number of subjects: 599
Study 15464665 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase
Number of subjects: 1764
Study 15464665 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of reteplase plus abciximab
Number of subjects: 1764
Study 15464665 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete ST-segment resolution (>70%)
Number of subjects: 1764
Study 15464665 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial ST-segment resolution (<70% to 30%)
Number of subjects: 1764
Study 15464665 — intervention group
Group type: EXPERIMENTAL
Intervention: No ST-segment resolution (<30%)
Number of subjects: 1764
Study 15464665 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening ST-segment elevation
Number of subjects: 1764
Study 15464665 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete ST-segment resolution (<70%)
Number of subjects: 1764
Study 12240674 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid sleep loss (0-hr TIB for 1 night)
Number of subjects: 12
Study 12240674 — intervention group
Group type: COMPARATOR
Intervention: Slow sleep loss (6-hr TIB for 4 nights)
Number of subjects: 12
Study 12240674 — intervention group
Group type: COMPARATOR
Intervention: Intermediate sleep loss (4-hr TIB for 2 nights)
Number of subjects: 12
Study 12240674 — intervention group
Group type: COMPARATOR
Intervention: No sleep loss (8-hr TIB for 4 nights)
Number of subjects: 12
Study 9735752 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-layer compression bandaging provided by district nurses
Number of subjects: 0
Study 7980882 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.5% in alcohol 70%
Number of subjects: 890
Study 7980882 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 890
Study 2638183 — intervention group
Group type: EXPERIMENTAL
Intervention: Test dentifrice containing 0.3% triclosan, 2% copolymer, and 0.76% sodium monofluorophosphate
Number of subjects: 3
Study 2638183 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 3
Study 49746 — intervention group
Group type: EXPERIMENTAL
Intervention: 95% ethanol solution containing 0‐5% chlorhexidine digluconate applied with a gloved hand for two minutes
Number of subjects: 0
Study 49746 — intervention group
Group type: COMPARATOR
Intervention: Traditional gauze applicator for operation sites
Number of subjects: 0
Study 49746 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous solution of chlorhexidine applied with a gloved hand
Number of subjects: 0
Study 49746 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% alcoholic solution of chlorhexidine applied with a gloved hand
Number of subjects: 0
Study 49746 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic povidone iodine applied with a gloved hand
Number of subjects: 0
Study 49746 — intervention group
Group type: EXPERIMENTAL
Intervention: 0‐5% chlorhexidine in 95% alcohol rubbed on and allowed to dry
Number of subjects: 0
Study 31958290 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab plus docetaxel (ram+doc)
Number of subjects: 1253
Study 31958290 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (doc)
Number of subjects: 1253
Study 31319165 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhospital bump trajectory (19.0%)
Number of subjects: 1897
Study 31319165 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained increase trajectory (17.6%)
Number of subjects: 1897
Study 31319165 — intervention group
Group type: EXPERIMENTAL
Intervention: Dip trajectory (14.5%)
Number of subjects: 1897
Study 31319165 — intervention group
Group type: EXPERIMENTAL
Intervention: No significant changes trajectory
Number of subjects: 1897
Study 31319165 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained increase without significant differences
Number of subjects: 1897